Biotech Values

[microcapfun]

[Analysts’ sales projections for Celsentri (a.k.a. maraviroc) are modest because it is assumed that the drug will be given only after other (safer) options have been exhausted.]

Yeah, but if somebody comes up with an orally bioavailable dual CCR5/CXCR4 inhibitor, that could be a first-line HIV blockbuster.

I don't understand why that should be particularly difficult. There are many CCR5 inhibitors in development and there are at a few CXCR4 inhibitors out there as well ...

AnorMED, recently acquired by Genzyme, has some CXCR4 inhibitors in late stage clinical trials, though they have had more luck using them to mobilize stem cells than as an anti-HIV therapy.

micro